Copyright
©The Author(s) 2021.
World J Hepatol. Aug 27, 2021; 13(8): 830-839
Published online Aug 27, 2021. doi: 10.4254/wjh.v13.i8.830
Published online Aug 27, 2021. doi: 10.4254/wjh.v13.i8.830
Table 1 Alternatives to the model for end-stage liver disease and model for end-stage liver disease-Na score
Test | Description | Comparison to MELD score | Ref. |
MELD-GRAIL | Creatinine replaced with GRAIL | Improved 90-d mortality predictor in patients with severe disease (MELD-Na > 32), however similar to MELD-Na in patient with lesser disease severity | Asrani et al[42,43], 2019 |
MELD-Lactate | Addition of lactate | Better predictor of in-hospital mortality when MELD < 15 or when infection is cause of hospitalization. Similar to MELD-Na in non-infectious admissions | Sarmast et al[44], 2020 |
Mahmud et al[45], 2021 | |||
MELD-Plus | Addition of albumin, total cholesterol, WBC count, age, and length of stay | Improved 90-d mortality predictor compared to MELD-Na, however can only be used after a hospital admission | Kartoun et al[46], 2017 |
CLIF-C ACLF | Score determined by six different organ systems failures, age and WBC count | Improved predictor of 28-d mortality compared to MELD-Na in patients with ACLF. However, only applicable for ACLF and not generalizable for decompensated cirrhosis | Jalan et al[51], 2014 |
Engelmann et al[52], 2018 | |||
Ramzan et al[53], 2020 |
- Citation: Polyak A, Kuo A, Sundaram V. Evolution of liver transplant organ allocation policy: Current limitations and future directions. World J Hepatol 2021; 13(8): 830-839
- URL: https://www.wjgnet.com/1948-5182/full/v13/i8/830.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i8.830